Key result
ERalpha agonist 16alpha-LE2 and 17beta-estradiol attenuate cardiac hypertrophy and boost cardiac output in hypertensive rats.
Why the study?
Does activation of ERalpha with 16alpha-LE2 attenuate cardiac hypertrophy and improve hemodynamic function in ovariectomized spontaneously hypertensive rats?
Does activation of ERalpha with 16alpha-LE2 attenuate cardiac hypertrophy and improve hemodynamic function in ovariectomized spontaneously hypertensive rats?
Activation of estrogen receptor-alpha with 16alpha-LE2 attenuates cardiac hypertrophy and improves myocardial contractility in a rat model of estrogen deficiency and hypertension.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ERα agonism in estrogen-deficient hypertension; leaves open human translation pending clinical studies.
OBJECTIVE: Cardiac mass increases with age and with declining estradiol serum levels in postmenopausal women. Although the non-selective estrogen receptor-alpha and -beta agonist 17beta-estradiol attenuates cardiac hypertrophy in animal models and in observational studies, it remains unknown whether activation of a specific estrogen receptor subtype (ERalpha or ERbeta) might give similar or divergent results. Therefore, we analyzed myocardial hypertrophy as well as cardiac function and gene expression in ovariectomized, spontaneously hypertensive rats (SHR) treated with the subtype-selective ERalpha agonist 16alpha-LE2 or 17beta-estradiol. METHODS AND RESULTS: Long-term administration of 16alpha-LE2 or 17beta-estradiol did not affect elevated blood pressure, but both agonists efficiently attenuated cardiac hypertrophy and increased cardiac output, left ventricular stroke volume, papillary muscle strip contractility, and cardiac alpha-myosin heavy chain expression. The observed effects of E2 and 16alpha-LE2 were abrogated by the ER antagonist ZM-182780. Improved left ventricular function upon 16alpha-LE2 treatment was also observed in cardiac MRI studies. In contrast to estradiol and 16alpha-LE2, tamoxifen inhibited cardiac hypertrophy but failed to increase alpha-myosin heavy chain expression and cardiac output. CONCLUSIONS: These results support the hypothesis that activation of ERalpha favorably affects cardiac hypertrophy, myocardial contractility, and gene expression in ovariectomized SHR. Further studies are required to determine whether activation ERbeta mediates redundant or divergent effects.
No takes yet. Share an insight, caveat, or question.
Pelzer et al. (2005) studied Cardiac hypertrophy. 16alpha-LE2 or 17beta-estradiol vs. Tamoxifen or untreated control was evaluated on Cardiac hypertrophy, cardiac output, left ventricular stroke volume, and contractility. The ERalpha agonist 16alpha-LE2 and 17beta-estradiol attenuated cardiac hypertrophy and increased cardiac output in ovariectomized spontaneously hypertensive rats.
Synapse has enriched 10 related papers. Consider them for comparative context: